BioSante (BPA.OB) – THE BIG REVEAL
Leading small-cap pharmaceutical company BioSante Pharmaceuticals (OTCBB: BPA) recently told Market News First about three new developments the company is looking at, and how they could affect the company's future.BioSante's CEO Stephen Simes discussed the news in a phone interview, particularly on the introduction of two new products in the BioSante product line: Eslestrin, a U.S. Food and Drug Administration (FDA) - approved estrodiol hormonal gel that Simes expects to be a competitive product in the $1.3 million marketplace; and LibiGel, a female sexual dysfunction gel. Simes said that the LibiGel product is extremely important at this point because it's…